A Phase 1 interventional study of TQF3250 capsules and TQF3250 placebo in Type 2 Diabetes Mellitus Combined With Overweight or Obesity, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 12 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 600 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.
Among the 600 studies in Obesity with a site in China, this one is the 328th largest by planned enrollment of the 502 interventional ones that give a count, is one of 134 that started in 2026, is one of 93 in phase 1, reaches primary completion later than 169 of the 280 other live ones, and was the 531st registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →221 of the 600 studies in Obesity with a site in China are open now. Recruiting first, the newest first:
Chendu DIAO Pharmaceutical Group CO., LTD. · Sites in China
Ages 18–65
The First Hospital of Jilin University · Sites in China
Ages 18–65
Pfizer · Sites in China
Ages 18+
Eli Lilly and Company · Sites in China, United States, Brazil and 7 more countries
Ages 18+
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–55
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
600 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 103 · Phase 2 70 · Phase 3 108 · Phase 4 28
First in 1997; this study’s year is marked. 134 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is close to the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 120 across the 502 interventional studies, 310 across the 98 observational. Of the 241 that completed or were terminated, 13 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
241 of 600 have an industry lead sponsor. The 10 most frequent:
This study is registered under Chia Tai Tianqing Pharmaceutical Group Co., Ltd., one of the names counted as Sino Biopharmaceutical Limited. Under that name alone:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.
Sino Biopharmaceutical Limited has 6 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
104 of the studies in Obesity with a site in China that are under way reach primary completion within a year, 20 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06974851Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity | 2026-12 |
| NCT06994650Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy | 2026-12 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07285902Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | 2027-03 |
Add all 104 to your calendar (.ics) → With an account.
Among the 600 studies in Obesity with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, placebo-controlled Phase 1b clinical study designed to evaluate the safety, tolerability, pharmacokinetic profiles and preliminary efficacy of multiple oral doses of TQF3250 capsules in trial subjects with type 2 diabetes mellitus complicated with overweight or obesity. A total of 72 eligible subjects are planned to be enrolled in this study.
Six treatment dose groups are established, including 4 mg, 8 mg, 12 mg, 24 mg, 32 mg and 40 mg, with a dose-escalation titration design. Each dose group will consist of 12 subjects. Eligible screened subjects will be randomized at a ratio of 10:2 (10 subjects receiving investigational drug and 2 subjects receiving placebo) to receive treatment with either TQF3250 capsules or matching placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
2.Able to provide written , and meet the following requirements:
Exclusion Criteria:
1.Other diabetic conditions besides type 2 diabetes mellitus
2.Other medical conditions and medical history
3.Concomitant and prior medications
4.Serological viral testing criteria
5.Abnormal physical or laboratory examination findings
6.Additional exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Six treatment dose groups (4 mg, 8 mg, 12 mg, 24 mg, 32 mg and 40 mg) are established in this study. A dose titration regimen is adopted for each group, where subjects are titrated from low doses to the target dose. Trial subjects will receive oral administration of TQF3250 capsules once daily (QD) under fasting conditions for a total treatment period of 12 weeks.
Drug: TQF3250 capsules
Trial subjects will receive oral administration of TQF3250 placebo once daily (QD) under fasting conditions for a total treatment period of 12 weeks.
Drug: TQF3250 placebo
An oral glucagon-like peptide-1 receptor agonist.
TQF3250-matched placebo capsules.
Adverse Event
Incidence and Severity of All Adverse Events (AEs), Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events (TEAEs).
Time frame: Baseline up to 14 weeks
Abnormal clinical examination findings
Incidence of abnormal clinical laboratory examination, vital signs, physical examination, 12-lead electrocardiogram,etc.
Time frame: Baseline up to 14 weeks
Area Under the Curve from 0 to 24 hours(AUC0-24h)
AUC0-24h following the first administration at target dose, and AUC0-24h after multiple administrations.
Time frame: Prior to dose on Day 1,8,15,22,29,36,50,64,78; 4-6 hours post-dose on Day 36,50,64,78. At target dose: Prior to 1st dose and 1,2,4,6,8,12,24 hours after. Prior to last dose and 1,2,4,6,8,12,24,48,96 hours after.
Area Under the Curve from time zero to infinity(AUC0-∞)
AUC0-∞ following the first administration at target dose, and AUC0-∞ after multiple administrations.
Time frame: Prior to dose on Day 1,8,15,22,29,36,50,64,78; 4-6 hours post-dose on Day 36,50,64,78. At target dose: Prior to 1st dose and 1,2,4,6,8,12,24 hours after. Prior to last dose and 1,2,4,6,8,12,24,48,96 hours after.
Area Under the Curve from time zero to the last quantifiable time point(AUC0-t)
Area Under the Curve from time zero to the last quantifiable time point(AUC0-t).
Time frame: Prior to dose on Day 1,8,15,22,29,36,50,64,78; 4-6 hours post-dose on Day 36,50,64,78. At target dose: Prior to 1st dose and 1,2,4,6,8,12,24 hours after. Prior to last dose and 1,2,4,6,8,12,24,48,96 hours after.
Maximum Plasma Concentration(Cmax)
Cmax following the first administration at target dose.
Time frame: Prior to dose on Day 1,8,15,22,29,36,50,64,78; 4-6 hours post-dose on Day 36,50,64,78. At target dose: Prior to 1st dose and 1,2,4,6,8,12,24 hours after. Prior to last dose and 1,2,4,6,8,12,24,48,96 hours after.
Minimum Steady-State Concentration(Css-min)
Css-min after multiple administrations.
Time frame: Prior to dose on Day 1,8,15,22,29,36,50,64,78; 4-6 hours post-dose on Day 36,50,64,78. At target dose: Prior to 1st dose and 1,2,4,6,8,12,24 hours after. Prior to last dose and 1,2,4,6,8,12,24,48,96 hours after.
Maximum Steady-State Concentration(Css-max)
Css-max after multiple administrations.
Time frame: Prior to dose on Day 1,8,15,22,29,36,50,64,78; 4-6 hours post-dose on Day 36,50,64,78. At target dose: Prior to 1st dose and 1,2,4,6,8,12,24 hours after. Prior to last dose and 1,2,4,6,8,12,24,48,96 hours after.
Average Steady-State Concentration(Css-avg)
Css-avg after multiple administrations.
Time frame: Prior to dose on Day 1,8,15,22,29,36,50,64,78; 4-6 hours post-dose on Day 36,50,64,78. At target dose: Prior to 1st dose and 1,2,4,6,8,12,24 hours after. Prior to last dose and 1,2,4,6,8,12,24,48,96 hours after.
Elimination Half-Life(t1/2)
t1/2 following the first administration at target dose and t1/2 after multiple administrations.
Time frame: Prior to dose on Day 1,8,15,22,29,36,50,64,78; 4-6 hours post-dose on Day 36,50,64,78. At target dose: Prior to 1st dose and 1,2,4,6,8,12,24 hours after. Prior to last dose and 1,2,4,6,8,12,24,48,96 hours after.
Time to Maximum Concentration(Tmax)
Tmax after multiple administrations
Time frame: Prior to dose on Day 1,8,15,22,29,36,50,64,78; 4-6 hours post-dose on Day 36,50,64,78. At target dose: Prior to 1st dose and 1,2,4,6,8,12,24 hours after. Prior to last dose and 1,2,4,6,8,12,24,48,96 hours after.
Apparent Oral Clearance (CL/F)
CL/F following the first administration at target dose and CL/F after multiple administrations.
Time frame: Prior to dose on Day 1,8,15,22,29,36,50,64,78; 4-6 hours post-dose on Day 36,50,64,78. At target dose: Prior to 1st dose and 1,2,4,6,8,12,24 hours after. Prior to last dose and 1,2,4,6,8,12,24,48,96 hours after.
Apparent Volume of Distribution during Elimination Phase(Vz/F)
Vz/F following the first administration at target dose.
Time frame: Prior to dose on Day 1,8,15,22,29,36,50,64,78; 4-6 hours post-dose on Day 36,50,64,78. At target dose: Prior to 1st dose and 1,2,4,6,8,12,24 hours after. Prior to last dose and 1,2,4,6,8,12,24,48,96 hours after.
Apparent Volume of Distribution at Steady State(Vss/F)
Vss/F after multiple administrations.
Time frame: Prior to dose on Day 1,8,15,22,29,36,50,64,78; 4-6 hours post-dose on Day 36,50,64,78. At target dose: Prior to 1st dose and 1,2,4,6,8,12,24 hours after. Prior to last dose and 1,2,4,6,8,12,24,48,96 hours after.
Terminal elimination rate constant(λz)
λz following the first administration at target dose and λz after multiple administrations.
Time frame: Prior to dose on Day 1,8,15,22,29,36,50,64,78; 4-6 hours post-dose on Day 36,50,64,78. At target dose: Prior to 1st dose and 1,2,4,6,8,12,24 hours after. Prior to last dose and 1,2,4,6,8,12,24,48,96 hours after.
Accumulation Ratio (Rac)
Rac after multiple administrations.
Time frame: Prior to dose on Day 1,8,15,22,29,36,50,64,78; 4-6 hours post-dose on Day 36,50,64,78. At target dose: Prior to 1st dose and 1,2,4,6,8,12,24 hours after. Prior to last dose and 1,2,4,6,8,12,24,48,96 hours after.
Dose Fluctuation(DF)
DF after multiple administrations.
Time frame: Prior to dose on Day 1,8,15,22,29,36,50,64,78; 4-6 hours post-dose on Day 36,50,64,78. At target dose: Prior to 1st dose and 1,2,4,6,8,12,24 hours after. Prior to last dose and 1,2,4,6,8,12,24,48,96 hours after.
Glycated hemoglobin(HbA1c)
Change from baseline in HbA1c and Proportion of participants with HbA1c ≤7.0% and HbA1c ≤6.5%.
Time frame: Week 4, Week 8, and Week 12
Oral Glucose Tolerance Test(OGTT)
Changes from baseline in C-peptide levels at each time point during the Oral Glucose Tolerance Test (OGTT), as well as changes from baseline in fasting plasma glucose (FPG) and 2-hour postprandial plasma glucose (2h-PPG).
Time frame: Week 12
Body Weight
Changes and percent change from baseline in body weight.
Time frame: Week 4, Week 8, and Week 12
Waist Circumference
Change from baseline in waist circumference.
Time frame: Week 4, Week 8, and Week 12
Body Mass Index(BMI)
Change from baseline in BMI.
Time frame: Week 4, Week 8, and Week 12
Fasting Plasma Glucose
Change from baseline in(FPG)
Time frame: Week 4, Week 8, and Week 12
C-peptide
Change from baseline in C-peptide.
Time frame: Week 4, Week 8, and Week 12
Insulin
Change from baseline in insulin.
Time frame: Week 4, Week 8, and Week 12
Started Aug 2026 (actual). Primary completion is estimated for Jun 2027, 10 months after the start.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 10 months is above that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TQF3250
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. →